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6.7 + 1.9 vs. 13 + 1.4”). Conclusions: 1. LV exhibits dominant “peristaltic”
segment lengths motion pattern of mechanical heterogeneity: apex-to-base
shortening and base-to-apex lengthening sequence; 2. Increased afterload
changes thia pattern to more homogeneouslengthening.
m99569 MagneticResonanceImagingAseeaamantofRegionalMyocardialFiberandCrosa-fiberStrain
D.C. Bloomgarden, V.A. Ferrari, A.A. Young, D.L. Kraitchman, Z.A. Fayad,
L. Axel. Urriv of PA, Phi/a., PA, USA, Urri~ of Auckland, Auck/and, AfZ,USA
Myocardial fiber orientations areorganized consistency.Noninvasive studies
(assuming homogeneous strain) and invasive canine studies under non-
physiological conditions have demonstrated greater subendocerdial cross-
fiber(XF) shortening than fiber shortening. We reexamined this phenomenon
using high resolution MRtegging and nonhomogeneous analysis under phys-
iological hemodynamic conditions. We imaged four normal dogs using MRI
with tissue tagging in shori and long axis planes. Three-dimensional finite el-
ement modeling was used to reconstruct the nonhomogeneous deformation
field of the entire LV.Strain was extracted from the model and referenced to
the fiber and XF directions, using a quantitative fiber field database, at all tag
intersections (- 1350/dog). Data were divided into 36 regions (3 longitudinal
levels, 4 circumferential sectors, and 3 transmural depths). The table shows
repreaentative average regional shortening straina at the midventricle. Fiber
strain varied by only 6’Yoover all regions, compared to 15% for XF strain. XF
strain was greater in the subendocardiurntha in the subepicardium in all
regions, and XF strain was greater than fiber strain throughout the suben-
docardium. High resolution MR tagging with nonhomogeneous 3D analyais
demonstrates striking differences in fiberafid cross-fiber strains in the normal
LV.
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Inhibitor on NitrateToleranceDuringTranedermal
Applicationof Nitroglycerin
H. Watanabe, M. Kakihana’, S. Ohtsuka, Y. Sugishite. LhWersityof
Tsukuh, Tsukubs,Japan, 1Ibaraki Prefectural Universi~ of’Health
Sciences, Ibsraki, Japan
Continuous application of nitroglycerin (NTG) has been shown to result in the
development of nitrate tolerance. The attenuation of intracellular production
of cGMP has been known aa an important mechanism of nitrate tolerance.
Thia study waa designed to investigate the effects of angiotenain mnverting
enzyme (ACE) inhibitors, captopril with a SH group and enalapril without a
SH group, on nitrate tolerance. in 15 patients with congestive heart failure,
platelet cGMPlevels (pmol/l OgPLT)andforearrmblood flow (FBF,mVmifVIOo
ml arm) by plethysmography were measured before and 5 minutes after
sublingual administration of 0.6 mg NTG at the following four phases: (1)
Control phase, (2) NTG phase (1 week after application of transdermal NTG
tape 10 m@24 hr), (S) CPT phase (1 week after both ceptopril 75 mg/day
and NTG tapa), and (4) ENL phase (1 week after both enalapril 10 m@day
and NTG tape). Before sublingual NTG, platelet cGMP levels (NTG: 0.44 +
0.12, CPT: 0.52+ 0.11, ENL: 0.41 + 0.18, p c 0.05 vs control, ANOVA) and
FBF (NTG: 3.3 + 0.5, CPT: 3.5 A 0.4, ENL: 3.5 + 0.5, p <0.05 va control,
ANOVA) were significantly higher at three phases with NTG tape than the
control phase (cGMP: 0.33 + 0.17, FBF: 2.7 + 0.5). The parentage of the
increase of platelet cGMP (% cGMP) and FBF (% FBF) after sublingual
NTG were significantly Iesa at the NTG phase than the control phase (ok
cGMP: 8 + 2 VS 36 + 5, p < 0.01; 7. FBF: 15 + 4 VS 32 + 8, p <0.01,
control phase va NTG phase). In contract, concomitant application with ACE
inhibitors maintained % cGMP (CPT:37+7, ENL: 30+5) and% FBF (CPT:
30& 8, ENL: 31 +7) campared with the control phase. Conclusions: These
results indicate that concomitant therapy with ACE inhibitore may be helpful
to prevent the attenuation of the production of cGMP and vasodilation during
continuous transdermal application of NTG.
IEEz.1ResponaeofB’ac’Hea~Fai’urepat’ent’toCarvediloi
C,Yancy, M.B. Fowler, W.S. Colucci, E.M. Gilbert, MA. Lukae, S.T.Young,
for the US Carvedilol Heart Failure Study Group. University of Texas
Southwestern, Da//as, TX, USA
To determine whether or not race might beaasociated with an altered efficacy
or safety profile when receiving therapy with p-blockade in heart failure, we
compared outcomea among black patiants randomized (double-blind) to
placebo or cervedilol (CRV), a multiple-action drug with & and a-blockade
and antioxidant properties, in the US Carvedilol Heart Failure Trials Program.
This study of 1,094 NYHA Class II-IV patients (LVEFs 35%), included 217
(20%) blacks (B), and 608 (74%) Caucasians (C). The mean exposure for C
(166 days) and B (167 days) was eimilar, during which existing therapy with
digoxin, diuretics andlor ACE inhibition was maintained.
Resu/ts: (Relative risk; 95% confidence intewals; interaction P value)
Race Mortality CardiovascularHospitali- WorseningHeart Failure
p = 0.s05 zation p = 0.342 Hospitalizationp = 0,714
c 0,34 (0.17, 0.67) 0.65 (0.46, 0.91) 0.52 (0.31, 0.S7)
B 0.53 (0,16, 1.52) 0.61 (0.29, 1,24) 0.47 (0.14, 1.61)
Adverse events associated with &blockade (fatigue [24% C, 18% B],
cardiac failure [16Y0C, 17Y0B] and bradycardia [7% C, 5% B]) were similar
in incidence although vasodilation (dizzineas [26% C, 33% B], hypotension
[9% C, 16% B]) waa less common in C.
Cone/usion:Blackpatients treated with CRV had similar reductions in their
risk of death and hospitalization, and exhibited a high degree of tolerability
of therapy.
1996-53] ShouidLowB100dPree5UreprGciIJdeinitiationOf
BetaBlockerTherapyinCongestiveHeartFailure?
J. Kalman, D.K. Levy, M.M. Mannino, R.S. Freudenberger, C. Buchholz,
O.N. Ocampo, M.L. Kukin. The Cardiovascular /nstitute, Mount Sirrai Scfroo/
of Medicine, New York,NY USA
There ia now accumulating evidence of the benefit of fl-blocker (P-B) therapy
in refracto~ heart failure. However, many physicians are un$feretandably
ralucfant to initiate B-B therapy when the systolic blood pressure (SBP)
is below IWJ mmHg. We compared the safaty and efficacy of metoprolol
according to the initial BP in 57 consecutive pts enrolled in B-B protocols.
All pts were on chronic background therapy (digoxin, diuretics, and ACEI)
with a pulmonary cspilla~ wedge pressure (PCW, mmHg) 214. There were
16 pts with SBP s 100 (Low BP) and 41 with SBP >100. Pts were NYHA
II - IV, with 70Y0 in NYHA Ill. Aside from BP derived variables, baseline
parameters were similar in both groups. Baseline (B) and 3 month (LT)
variables of SBP, heart rate (HR, bpm), PCW, aystemic vascular resistance
(SVR, d-s-c), stroke work index (SWI, gm-rnlm2), and ejection fraction (EF)
are shown. (*p <0.05 vs. B w/in grp, #p <0.05 btw grp B to LT)
SBP HR Pcw SJR Swl EF
Low BP: S 94 S9 26 1211 16.5 In
Low BP: LT 101” 67* 18” 1055 31.5* ‘-14*
BP> 100: B 118 Ss 2s 1330 23.1 13
BP > 100: LT 112*# 71” 21” 996* 32,4* “-18*
Nine pts did not complete the study (5: SBP > 100,4: Low BP; p = NS).
The average $ in NYHAwas 1 class while submaximal and maximal exercise
Tin both grps (btw grps; p = NS).
In summary, both grps improved with O-Btherapy with no btw grp differ-
ence in response other than the surprising T in SBP in the low BP grp. Thus,
asymptomatic hypotension does not preclude initiation or response to P-B
therapy.
-1 Threa-YearFoiiOv+UpOf~h.MetoPrololinDiiated
CardiomyopathyTrial
B. Andereson, F.Waagstain. Div. of Cardiology, Sah/grenska University
Hospital, G6teborg, Sweden
The international multicenter Metoprolol in Dilated Cardiomyopathy (MDC)
trial was the first major placabo-controlled trial using beta-blcckera in con-
gestive hea~ failure. The study recruited 383 patients with idiopathic dilated
cardiomyopathy. During the 18 months of the study there was a 34% re-
duction in the primary endpoint, death or need for haarf transplantation (p=
0.058). The aim of the present investigation was to evaluate long-term follow-
up in patients participating in the MDC-trial. Death or heart transplantation
was considered as endpoint.
